5 Key Takeaways

• 1

  Tacrolimus achieved higher remission rates than infliximab at 8 weeks in patients with refractory ulcerative colitis.

• 2

  The study included 241 patients, with 90 receiving tacrolimus and 151 receiving infliximab, all with corticosteroid-refractory UC.

• 3

  Cumulative colectomy-free survival was significantly lower for tacrolimus at 79.4% compared to 93.7% for infliximab at 12 months.

• 4

  Predictors of colectomy in tacrolimus-treated patients included serum albumin levels ≤3.5 g/dL at week 8.

• 5

  The study's limitations include its retrospective nature and the inability to fully adjust for unmeasured confounders.